Shift in AP-2α localization characterizes astrocytoma progression

Cancer Biology and Therapy

Volumn 6, Issue 3, 2007, Pages 413-418

  Britto, Ramona ^a   Umesh, S ^b   Hegde, A S ^c   Hegde, Sridevi ^d   Santosh, Vani ^b   Chandramouli, B A ^b   Somasundaram, Kumaravel ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^c SRI SATHYA SAI INSTITUTE OF HIGHER MEDICAL SCIENCES   (India)

^d MANIPAL HOSPITAL   (India)

Author keywords

AP 2; Astrocytoma; Cancer; Glioblastoma multiforme; Glioma

Indexed keywords

ACTIVATOR PROTEIN 2ALPHA; MESSENGER RNA; RNA; TRANSCRIPTION FACTOR AP 2; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER GROWTH; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; BRAIN TUMOR; CHEMISTRY; DISEASE COURSE; GENETICS; METABOLISM; PATHOLOGY; PROTEIN TRANSPORT;

ASTROCYTOMA; BRAIN NEOPLASMS; CELL NUCLEUS; CYTOPLASM; DISEASE PROGRESSION; HUMANS; PROGNOSIS; PROTEIN TRANSPORT; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-2;

EID: 34548293704     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.3.3756     Document Type: Article

References (35)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49:8-31.
2. Mischel P, Vinters HV. In: Mea LL. Brain Tumor Immunotherapy 2001; 3-45.
3. Nagane M, Huang HJ, Cavenee WK. Advances in the molecular genetics of gliomas. Curr Opin Oncol 1997; 9:215-22.
4. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, Bar-Eli M. Loss of the AP-2a Transcription Factor Is Associated with the Grade of Human Gliomas. Clin Cancer Res 2005; 11:267-72.
5. Frederick L, Wang XY, Eley G and James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000; 60:1383-7.
6. Campomenosi P, Ottaggio L, Moro F, Urbini S, Bogliolo M, Zunino Camoriano A, Inga A, Gentile SL, Pellegata NS, Bonassi S, Bruzzone E, Iannone R, Pisani R, Menichini P, Ranzani GN, Bonatti S, Abbondandolo A, Fronza G. Study on aneuploidy and p53 mutations in astrocytomas. Cancer Genet Cytogenet, 1996; 8:95-102.
7. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, Yonekawa Y, Kleihues P, Ohgaki H. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997; 3:523-30.
8. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, Wiestler OD, Louis DN, Fimmers R, von Deimling A. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002; 61:321-28
9. Reavey-Cantwell JF, Haroun RI, Zahurak M, Clatterbuck RE, Parker RJ, Mehta R, Fruehauf JP, Brem H. The prognostic value of tumor markers in patients with glioblastoma multiforme : analysis of 32 patients and review of the literature. J Neurooncol 2001; 55:195-204.
10. Shiraishi S, Tada K, Nakamura H, Makino K, Kochi M, Saya H, Kuratsu J, Ushio Y. Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 2002; 95:249-57.
11. Pollack I, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL Yates AJ, Boyett JM, Finlay JL, Sposto R; Children's Cancer Group. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 2002; 346:420-7.
12. Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, Prados M, Berger M, Passe S, Uhm J, O'Neill BP, Jenkins RB, Aldape KD. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 2002; 8:180-7.
13. Hilger-Eversheim K, Moser M, Schorle H, Buettner R. Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene 2000; 260:1-12.
14. Piao Z, Lee KS, Kim H, Perucho M, Malakhosyan S. Identification of novel deletion regions on chromosome arms 2q and 6p in breast carcinomas by amplotype analysis. Genes Chromosomes Cancer 2000: 113-22.
15. Kannan P, Buettner R, Chiao PJ, Yim SO, Sarkiss M, Tainsky MA. N-ras oncogene causes AP-2 transcriptional self-interference, which leads to transformation. Genes Dev 1994;8:1258-69.
16. Antilla MA, Kellokoski JK, Moisio KI, Mitchell PJ, Saarikoski S, Syrjanen K, Kosma VM. Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer. Br J Cancer 2000;82: 1974-83.
17. Douglas DB, AkiyamaY, Carraway H, Belinsky SA, Esteller M, Gabrielson E, Weitzman S, Williams T, Herman JG, Baylin SB. Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer. Cancer Res 2004;64: 1611-20.
18. Gee JM, Robertson JF, Ellis IO, Nicholson RI, Hurst HC. Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor ap-2 in invasive breast cancer. J Pathol 1999;189: 514-20.
19. Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, Tainsky MA, Bar-Eli M. Loss of AP-2 results in upregulation of MCAM/MUC8 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 1998; 273:16501-08.
20. Ropponen KM, Kellokoski JK, Pirinen RT, Moisio KI, Eskelinen MJ, Alhava EM, Kosma VM. Expression of transcription factor AP-2 in colorectal adenomas and adenocarcinomas; comparison of immunohistochemistry and in situ hybridisation. J Clin Pathol 2001; 54:533-38.
21. Ruiz M, Pettaway C, Song R, Stoeltzing O, Ellis L, Bar-Eli M. Activator protein 2a inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Res 2004; 64:631-8.
22. Tellez C, McCarty M, Ruiz M, Bar-Eli M. Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem 2003; 278: 46632-42.
23. Zeng YX, Somasundaram K, El-Deiry WS. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet 1997; 15:78-82.
24. Wajapeyee N, Somasundaram K. Cell cycle arrest and apoptosis induction by activator protein 2alpha (AP-2alpha) and the role of p53 and p21WAF1/CIP1 in AP-2alpha-mediated growth inhibition. J Biol Chem 2003; 278:52093-101.
25. Wajapeyee N, Raut CG, Somasundaram K. Activator protein 2 alpha status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy. Cancer Res 2005; 65:8628-34.
26. Wajapeyee N, Britto R, Ravishankar HM, Somasundaram K. Apoptosis induction by activator protein 2alpha involves transcriptional repression of Bcl-2. J Biol Chem 2006; 281:16207-19.
27. Kleihues P, Burger PC, Collins VP, Ohgaki H, Cavenee WK. Glioblastoma. Pathology and Genetics of Tumors of Nervous System Lyon; 2000: 29-39.
28. Somasundaram K, Reddy SP, Vinnakota K, Britto R, Subbarayan M, Nambiar S, Hebbar A, Samuel C, Shetty M, Sreepathi HK, Santosh V, Hegde AS, Hegde S, Kondaiah P, Rao MR. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene 2005; 24:7073-83.
29. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:9.
30. Pellikainen J, Kataja V, Ropponen KM, Kellokoski JK, Pietilainen T, Bohm J, Eskelinen MJ, Kosma VM. Reduced Nuclear Expression of Transcription Factor AP-2 Associates with Aggressive Breast Cancer. Clin Cancer Res 2002; 8:3487-95.
31. Buettner R, Kannan P, Imhof A, Bauer R, Yim SO, Glockshuber R, Van Dyke MW, Tainsky MA. An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2. Mol Cell Biol 1993; 13:4174-85.
32. Mazina OM, Phillips MA, Williams T, Vines CA, Cherr GN, Rice RH. Redistribution of Transcription Factor AP-2a in Differentiating Cultured Human Epidermal Cells. J Invest Dermatol 2001; 117:864-70.
33. Karin M, Hunter T. Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Curr Biol 1995; 7:747-57.
34. Anttila MA, Kosma VM, Hongxiu J, Puolakka J, Juhola M, Saarikoski S, Syrjanen K. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer 1999; 79:1870-8.
35. Soong R, Knowles S, Williams KE, Hammond IG, Wysocki SJ, Iacopetta BJ. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 1996; 74:562-67.